All it takes is a little volume and upcoming catalysts should provide that.
MEI Pharma, Inc. (MEIP), will be presenting data on Pracinostat, in combination with azacitidine in patients with advanced myelodysplastic syndrome (MDS) at a poster presentation at the American Society of Hematology Annual Meeting on December 10, 2012.
Stock looks good for at least a $.50 pop
Our search through databases at the United States Patent and Trademark Office appear to show that Local was recently granted a U.S. patent to further monetize the $2.7 Billion mobile advertising market. Monetizing mobile is big and investors are following who owns the IP real estate in this market.
This patent ...
$EXEL shares starting to break-out.FDA decision scheduled to Nov. 29. "optimists like cabozantinib's chances for approval" says Motley Fool. Looks like negative over-all market conditions weighing in on the stock move. Watch this one! ...
LOCM shares appear to be breaking out. Pending news and any influx of volume could really push shares much higher here. There appears to be very little overhang here as the stock trades very freely. Fundamentally, the stock appears to be undervalued as well, so we see this as a big upside/low risk trade. $LOCM